1. What conditions has Magnolia Bark been studied for?

• Depression (mild–moderate, as phytotherapy): Magnolia bark is mentioned among herbal agents with preclinical and some clinical evidence for antidepressant activity in a narrative review of phytopharmacotherapy for depression.

• Oral/dental diseases: Studied against oral pathogens and oral biofilms, including:

  • Dental caries risk / Streptococcus mutans: magnolol and honokiol tested against planktonic cells and biofilm.

  • Periodontitis (adjunctive phytotherapy): Magnolia bark included in a review of plant materials used for periodontitis management.

  • General oral pathogens / MRSA-related mechanisms: honokiol and magnolol evaluated for antimicrobial activity, biofilm inhibition, and effects on antibiotic-resistance gene expression.

• Doxorubicin-induced cardiotoxicity: A magnolia bark extract complex (magnolol + honokiol; MAHOC) studied in rats exposed to doxorubicin.

• Type 2 diabetes-related complications and metabolic disease:

  • Hyperglycemia/metabolic disease via PPARγ: honokiol studied as a partial PPARγ agonist in vitro and in diabetic mice.

  • Diabetes-related male reproductive/testicular oxidative stress: honokiol and magnolol studied in a rat model of type 2 diabetes.

• Silicosis / lung inflammation, pyroptosis, and fibrosis: honokiol studied in a mouse silicosis model and in macrophages, focusing on cGAS/STING signaling.

• Inflammation (cell models): honokiol and magnolol reduced pro-inflammatory gene expression in RAW264.7 cells (macrophage line) in an oral-pathogen-focused study.

2. Does it work in treating those conditions? Summarize the evidence.

• Depression: The depression abstract is a narrative (non-systematic) review stating that preclinical and “previous clinical studies” support antidepressant activity of magnolia bark constituents and that mechanisms may overlap with synthetic antidepressants (e.g., monoamine reuptake/MAO effects and receptor actions), with anti-inflammatory effects also highlighted. However, the study does not provide magnolia-specific trial details (dose, outcomes, effect size), so efficacy for depression cannot be firmly concluded from these studies alone.

• Dental/oral antimicrobial effects:

  • S. mutans (caries-related): In vitro, magnolol and honokiol inhibited S. mutans (MIC 10 µg/mL for each; chlorhexidine MIC 0.25 µg/mL). They showed bactericidal activity and inhibited biofilm formation dose- and time-dependently. Magnolol at 50 µg/mL showed greater bactericidal activity against established biofilm than honokiol (50 µg/mL) and chlorhexidine (500 µg/mL) at 5 minutes, and magnolol/honokiol were less cytotoxic to gingival epithelial cells than chlorhexidine under the tested conditions.

  • Broader oral pathogens/biofilm and resistance markers: Another in vitro study found honokiol had stronger antimicrobial activity than magnolol; both were stable across temperature/pH ranges, reduced biofilm formation, reduced antibiotic-resistance gene expression in MRSA, and repressed pro-inflammatory gene expression in RAW264.7 cells. These findings support plausibility for oral-health applications, but they are not clinical outcomes.

  • Periodontitis: A review lists magnolia bark among botanicals with antibacterial/anti-inflammatory/antioxidant activities relevant to periodontitis management, but the study does not provide magnolia-specific clinical efficacy data.

• Doxorubicin cardiotoxicity (rats): In a rat model, MAHOC (100 mg/kg) given before or after doxorubicin improved survival (reported “full survival” during 12–14 weeks), improved systemic oxidative/antioxidant status markers and blood pressure, improved cardiac functional parameters (e.g., end-diastolic volume, LV end-systolic volume, heart rate, cardiac output), and improved histologic injury markers. Benefits were more prominent with pre-treatment. This is supportive but remains preclinical.

• Metabolic disease / hyperglycemia: Honokiol directly bound PPARγ and acted as a partial agonist in a reporter assay. It stimulated glucose uptake in adipocytes similarly to pioglitazone but did not induce adipogenesis in tested cell models (unlike pioglitazone). In diabetic KKAy mice, oral honokiol prevented hyperglycemia and suppressed weight gain. This supports metabolic benefit in animals and mechanistic plausibility, but it is not a human efficacy trial.

• Diabetes-related testicular oxidative stress (rats): In type 2 diabetic rats, oral honokiol or magnolol (5 or 25 mg/kg for 4 weeks) improved oxidative stress-related parameters in testes and polyol pathway/glycation-related measures locally, but showed no favorable effects on serum biochemical parameters. Magnolol appeared more advantageous than honokiol for reversing testicular complications in this model.

• Silicosis/lung fibrosis and pyroptosis (mice + cells): Honokiol reduced lung inflammation, collagen deposition, and oxidative stress in a mouse silicosis model and reduced pyroptosis in vivo and in macrophages, attributed to suppression of the cGAS/STING pathway. This is promising but preclinical.

3. What health benefits does it have?

• Antioxidant and anti-inflammatory effects: Multiple studies describe magnolia bark constituents (magnolol/honokiol) as antioxidant-like and anti-inflammatory, including reduced oxidative stress markers in animal disease models and repression of pro-inflammatory gene expression in macrophage cells.

• Oral health support (mechanistic/in vitro): Antimicrobial activity against oral pathogens, inhibition of biofilm formation, and potential reduction of antibiotic-resistance gene expression (in vitro). Magnolol/honokiol also showed lower cytotoxicity than chlorhexidine in one gingival epithelial cell model at tested exposures.

• Cardioprotective potential in chemotherapy-related injury (preclinical): In rats, a magnolia bark extract complex improved survival, cardiac function, and cardiac tissue injury markers in doxorubicin cardiotoxicity.

• Metabolic benefits (preclinical): Honokiol acted as a partial PPARγ agonist, improved glucose uptake in vitro, and in diabetic mice prevented hyperglycemia while suppressing weight gain (suggesting a potentially favorable profile versus full PPARγ agonists that can promote weight gain).

• Potential protection against diabetes-related reproductive oxidative damage (preclinical): Honokiol and magnolol improved oxidative stress and related pathways in testes in diabetic rats (with magnolol appearing more beneficial in that study).

• Anti-fibrotic/anti-pyroptotic potential in lung injury (preclinical): Honokiol reduced fibrosis-related pathology and pyroptosis signaling in a silicosis model via cGAS/STING pathway suppression.

• Sedative effects (traditional use): One review notes magnolia bark extracts are widely used for sedative effects in traditional medicine, though the studies reviewed here do not include controlled clinical sedation outcomes.

4. Does it have any downsides or side effects?

• Overall safety signals (as summarized in a safety review): A review of magnolol/honokiol and concentrated magnolia bark extract reports:

  • No mutagenic/genotoxic potential in in vitro and in vivo genotoxicity studies for concentrated extract.

  • A subchronic OECD-guideline study found a NOAEL > 240 mg/kg body weight/day for concentrated extract (species not specified in the study).

  • Intervention trials using concentrated extract for up to 1 year did not report adverse effects (details not provided in the study).

  • Food safety authorities have evaluated magnolol and honokiol and considered them safe (as stated in the review).

• Potential drug interactions (theoretical/uncertain): The safety review notes magnolol/honokiol undergo glucuronidation and have relatively quick clearance, but interactions with pharmaceuticals or other herbal constituents cannot be excluded. This is a limitation: the studies do not specify which drugs or the magnitude of interaction risk.

• Product variability: The magnolol/honokiol content varies by Magnolia species, origin, plant part, and extraction method, which can affect both efficacy and safety consistency across supplements.

• Evidence gaps: Many benefits described here are from cell and animal studies. Lack of robust human efficacy data for several indications is a practical downside when considering supplementation for treatment purposes.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

• No direct pharmacogenomic evidence in the studies reviewed here: None of the studies report outcomes stratified by genotype or specific gene variants affecting response or adverse effects.

• Mechanistic hints but not genotype-specific: The studies implicate pathways such as PPARγ activation (honokiol as a partial agonist) and cGAS/STING signaling suppression (honokiol in silicosis models). While genetic variation in these pathways could plausibly influence response, the provided evidence does not test or confirm any such relationships.

• Metabolism note (not genotype-linked here): The safety review notes magnolol/honokiol are subject to glucuronidation. Genetic variation in glucuronidation enzymes (e.g., UGTs) could theoretically alter exposure, but the studies do not provide data connecting UGT genotypes to magnolia constituent pharmacokinetics or safety.

Summary of Magnolia Bark Extract Research

Magnolia bark extract, particularly the compound honokiol, plays a crucial role in the anxiolytic and antidepressant effects of traditional Chinese and Japanese Kampo medicines. Research has demonstrated that honokiol is responsible for the anxiety-reducing properties of Hange-koboku-to and Saiboku-to, as its removal from these medicines resulted in the loss of anxiolytic effects. Honokiol has also shown antidepressant-like effects in rodents, countering depression-related biochemical changes.

Further studies have isolated and purified honokiol and magnolol from Magnolia officinalis, confirming their high purity and potential for further investigation into their interaction with depression-related biological systems. The compounds have been subjected to various methods for assessing quality, with magnolol and honokiol being critical for differentiating between samples of Magnoliae officinalis Cortex.

In addition to mental health, honokiol and magnolol have been studied for their effects on cancer, inflammation, and oxidative stress. Honokiol, for instance, can cross the blood-brain barrier and inhibit the growth of brain tumors, offering a promising new therapy for gliosarcoma. It has also been found to enhance GABA(A) receptor activity, contributing to its anxiolytic and central depressant effects.

Overall, the extract from Magnolia bark and its compounds, honokiol and magnolol, possess a range of pharmacological effects, making them subjects of interest for the potential treatment of various conditions, including anxiety, depression, and cancer.

References:

1. The anxiolytic effect of two oriental herbal drugs in Japan attributed to honokiol from magnolia bark
2. Asthma as well as anxiety improved by the Kampo extract Saiboku-to
3. Antidepressant effects of Banxia Houpu decoction, a traditional Chinese medicinal empirical formula
4. Antidepressant-like effects of the mixture of honokiol and magnolol from the barks of Magnolia officinalis in stressed rodents
5. Isolation and purification of honokiol and magnolol from cortex Magnoliae officinalis by high-speed counter-current chromatography
6. Quality assessment of commercial Magnoliae officinalis Cortex by ¹H-NMR-based metabolomics and HPLC methods
7. A comparative study of upright counter-current chromatography and high-performance liquid chromatograpohy for preparative isolation and purification ofphenolic compounds from Magnoliae officinalis
8. [Effects of primary processing on quality of cortex Magnolia officinalis]
9. Anxiolytic-like effects of 4-O-methylhonokiol isolated from Magnolia officinalis through enhancement of GABAergic transmission and chloride influx
10. Studies on the alkaloids of the bark of Magnolia officinalis: isolation and on-line analysis by HPLC-ESI-MS(n)
11. Effects of constituents from the bark of Magnolia obovata on nitric oxide production in lipopolysaccharide-activated macrophages
12. Metabolites of orally administered Magnolia officinalis extract in rats and man and its antidepressant-like effects in mice
13. Phenolic glycosides and other constituents from the bark of Magnolia officinalis
14. [Variation of phenolic compound contents of Magnolia officinalis at different levels]
15. [Phenols in seedling cortex of Magnolia officinalis from Enshi]
16. Studies on the active principles of magnolia bark. Centrally acting muscle relaxant activity of magnolol and hōnokiol
17. Therapeutic applications of compounds in the Magnolia family
18. [Studies on the components of Magnolia obovata Thunb. 3. Occurrence of magnolol and hõnokiol in M. obovata and other allied plants]
19. Comparative studies on the interactions of honokiol and magnolol with human serum albumin
20. Systematic analysis of post-administrative saiboku-to urine by liquid chromatography to determine pharmacokinetics of traditional Chinese medicine
21. Disposition of magnolol after intravenous bolus and infusion in rabbits
22. Pharmacokinetics and brain distribution of magnolol in the rat after intravenous bolus injection
23. Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model
24. Honokiol and magnolol increase the number of [3H] muscimol binding sites three-fold in rat forebrain membranes in vitro using a filtration assay, by allosterically increasing the affinities of low-affinity sites
25. Effects of honokiol and magnolol on acetylcholine release from rat hippocampal slices
26. Honokiol and magnolol increased hippocampal acetylcholine release in freely-moving rats
27. Protective effect of the ethanol extract of Magnolia officinalis and 4-O-methylhonokiol on scopolamine-induced memory impairment and the inhibition of acetylcholinesterase activity
28. Magnolol and honokiol prevent learning and memory impairment and cholinergic deficit in SAMP8 mice
29. The natural products magnolol and honokiol are positive allosteric modulators of both synaptic and extra-synaptic GABA(A) receptors
30. Modulation of GABAA-receptors by honokiol and derivatives: subtype selectivity and structure-activity relationship
31. Magnolol enhances pentobarbital-induced sleeping behaviors: possible involvement of GABAergic systems
32. Magnolol, a major bioactive constituent of the bark of Magnolia officinalis, exerts antiepileptic effects via the GABA/benzodiazepine receptor complex in mice
33. Magnolol, a major bioactive constituent of the bark of Magnolia officinalis, induces sleep via the benzodiazepine site of GABA(A) receptor in mice
34. Differential inhibitory effects of honokiol and magnolol on excitatory amino acid-evoked cation signals and NMDA-induced seizures
35. Effects of extract and ingredients isolated from Magnolia obovata thunberg on catecholamine secretion from bovine adrenal chromaffin cells
36. Interactions of Magnolia and Ziziphus extracts with selected central nervous system receptors
37. Protective and restorative effects of magnolol on neurotoxicity in mice with 6-hydroxydopamine-induced hemiparkinsonism
38. Magnolol decreases body temperature by reducing 5-hydroxytryptamine release in the rat hypothalamus
39. Modulatory effects of magnolol on potassium-stimulated 5-hydroxytryptamine release from rat cortical and hippocampal slices
40. Antidepressant-like synergism of extracts from magnolia bark and ginger rhizome alone and in combination in mice
41. Pharmacological properties of magnolol and honokiol extracted from Magnolia officinalis: central depressant effects
42. The clinical presentation of generalized anxiety in primary-care settings: practical concepts of classification and management
43. Effect of a proprietary Magnolia and Phellodendron extract on stress levels in healthy women: a pilot, double-blind, placebo-controlled clinical trial
44. Randomized controlled study on clinical efficacy of isoflavones plus Lactobacillus sporogenes, associated or not with a natural anxiolytic agent in menopause
45. Soy isoflavones, lactobacilli, Magnolia bark extract, vitamin D3 and calcium. Controlled clinical study in menopause
46. Effect of a proprietary Magnolia and Phellodendron extract on weight management: a pilot, double-blind, placebo-controlled clinical trial
47. Antidepressant-like effect of magnolol on BDNF up-regulation and serotonergic system activity in unpredictable chronic mild stress treated rats
48. Combined administration of the mixture of honokiol and magnolol and ginger oil evokes antidepressant-like synergism in rats
49. Effects of magnolol (5,5'-diallyl-2,2'-dihydroxybiphenyl) on diabetic nephropathy in type 2 diabetic Goto-Kakizaki rats
50. Review of the expression of peroxisome proliferator-activated receptors alpha (PPAR alpha), beta (PPAR beta), and gamma (PPAR gamma) in rodent and human development
51. Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance
52. PPARs and the complex journey to obesity
53. Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (γ) agonist
54. MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema
55. N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo
56. Computer-aided discovery, validation, and mechanistic characterization of novel neolignan activators of peroxisome proliferator-activated receptor gamma
57. Honokiol: a non-adipogenic PPARγ agonist from nature
58. Honokiol enhances adipocyte differentiation by potentiating insulin signaling in 3T3-L1 preadipocytes
59. PPAR-RXR heterodimer activates a peroxisome proliferator response element upstream of the bifunctional enzyme gene
60. Magnolol enhances adipocyte differentiation and glucose uptake in 3T3-L1 cells
61. Long-term supplementation of honokiol and magnolol ameliorates body fat accumulation, insulin resistance, and adipose inflammation in high-fat fed mice
62. Prevalence of periodontitis in adults in the United States: 2009 and 2010
63. Host-parasite interactions in periodontitis: subgingival infection and host sensing
64. Aggregatibacter actinomycetemcomitans as indicator for aggressive periodontitis by two analysing strategies
65. Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis
66. Magnolol ameliorates ligature-induced periodontitis in rats and osteoclastogenesis: in vivo and in vitro study
67. Antimicrobial activity of magnolol and honokiol against periodontopathic microorganisms
68. Antimicrobial activity of honokiol and magnolol isolated from Magnolia officinalis
69. Magnolol stimulates lipolysis in lipid-laden RAW 264.7 macrophages
70. The anti-inflammatory effect of honokiol on neutrophils: mechanisms in the inhibition of reactive oxygen species production
71. Protective effects of honokiol and magnolol on tertiary butyl hydroperoxide- or D-galactosamine-induced toxicity in rat primary hepatocytes
72. Honokiol, a multifunctional antiangiogenic and antitumor agent
73. Comparison of antioxidant abilities of magnolol and honokiol to scavenge radicals and to protect DNA
74. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo
75. Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway
76. The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells
77. Shb gene knockdown increases the susceptibility of SVR endothelial tumor cells to apoptotic stimuli in vitro and in vivo
78. Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis
79. Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells
80. Targeting apoptosis pathways in cancer with magnolol and honokiol, bioactive constituents of the bark of Magnolia officinalis
81. Honokiol induces calpain-mediated glucose-regulated protein-94 cleavage and apoptosis in human gastric cancer cells and reduces tumor growth
82. Honokiol induces apoptosis through p53-independent pathway in human colorectal cell line RKO
83. Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest
84. Honokiol, a constituent of oriental medicinal herb magnolia officinalis, inhibits growth of PC-3 xenografts in vivo in association with apoptosis induction
85. Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells
86. Enhancement of therapeutic effectiveness by combining liposomal honokiol with cisplatin in ovarian carcinoma
87. Improved solubility and pharmacokinetics of PEGylated liposomal honokiol and human plasma protein binding ability of honokiol
88. Improved therapeutic effectiveness by combining liposomal honokiol with cisplatin in lung cancer model
89. Honokiol induces a necrotic cell death through the mitochondrial permeability transition pore
90. Down-modulation of Bcl-XL, release of cytochrome c and sequential activation of caspases during honokiol-induced apoptosis in human squamous lung cancer CH27 cells
91. Natural flavonoids and lignans are potent cytostatic agents against human leukemic HL-60 cells
92. Honokiol induces apoptosis in human lymphoid leukemia Molt 4B cells
93. Behavioral and biochemical studies on chronic mild stress models in rats treated with a Chinese traditional prescription Banxia-houpu decoction
94. Orthogonal array design for antidepressant compatibility of polysaccharides from Banxia-Houpu decoction, a traditional Chinese herb prescription in the mouse models of depression
95. Depression and Its Phytopharmacotherapy-A Narrative Review.
    Lukasz Dobrek, Krystyna Głowacka (2023) - International journal of molecular sciences
96. Safety and Toxicology of Magnolol and Honokiol
    Andrea Sarrica, Natalja Kirika, Margherita Romeo, Mario Salmona, Luisa Diomede (2018)
97. In vitro antimicrobial and antipro-inflammation potential of honokiol and magnolol against oral pathogens and macrophages.
    Kuo-Chou Chiu, Yin-Hwa Shih, Tong-Hong Wang, Wan-Chen Lan, Po-Jung Li, Hong-Syu Jhuang, Shih-Min Hsia, Yen-Wen Shen, Michael Yuan-Chien Chen, Tzong-Ming Shieh (2021) - Journal of the Formosan Medical Association = Taiwan yi zhi
98. Cardioprotective role of a magnolol and honokiol complex in the prevention of doxorubicin-mediated cardiotoxicity in adult rats.
    Irem Aktay, Ceylan Verda Bitirim, Yusuf Olgar, Aysegul Durak, Erkan Tuncay, Deniz Billur, Kamil Can Akcali, Belma Turan (2024) - Molecular and cellular biochemistry
99. Beneficial effect of honokiol and magnolol on polyol pathway and oxidative stress parameters in the testes of diabetic rats.
    Katarzyna Szałabska-Rąpała, Maria Zych, Weronika Borymska, Piotr Londzin, Sławomir Dudek, Ilona Kaczmarczyk-Żebrowska (2024) - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
100. Can Plant Materials Be Valuable in the Treatment of Periodontal Diseases? Practical Review.
     Anna Gościniak, Magdalena Paczkowska-Walendowska, Agnieszka Skotnicka, Marek A Ruchała, Judyta Cielecka-Piontek (2021) - Pharmaceutics
101. Anti-biofilm and bactericidal effects of magnolia bark-derived magnolol and honokiol on Streptococcus mutans.
     Yuuki Sakaue, Hisanori Domon, Masataka Oda, Shoji Takenaka, Miwa Kubo, Yoshiyasu Fukuyama, Takashi Okiji, Yutaka Terao (2016) - Microbiology and immunology
102. Honokiol ameliorates silica-induced lung fibrosis by inhibiting macrophage pyroptosis via modulating cGAS/STING signaling.
     Qiang Zhou, Meiyu Chang, Shuhan Guo, Yiming Zhang, Qiufang Qu, Qingnan Zhou, Zhiheng Li, Sanqiao Yao (2025) - International immunopharmacology
103. Honokiol protects against doxorubicin cardiotoxicity via improving mitochondrial function in mouse hearts.
     Lizhen Huang, Kailiang Zhang, Yingying Guo, Fengyuan Huang, Kevin Yang, Long Chen, Kai Huang, Fengxue Zhang, Qinqiang Long, Qinglin Yang (2017) - Scientific reports
104. Effectiveness of Magnolol, a Lignan from Magnolia Bark, in Diabetes, Its Complications and Comorbidities-A Review.
     Katarzyna Szałabska-Rąpała, Weronika Borymska, Ilona Kaczmarczyk-Sedlak (2021) - International journal of molecular sciences
105. Effects of isoflavones and amino acid therapies for hot flashes and co-occurring symptoms during the menopausal transition and early postmenopause: a systematic review.
     Annette J Thomas, Rita Ismail, Lisa Taylor-Swanson, Lori Cray, Janet G Schnall, Ellen Sullivan Mitchell, Nancy Fugate Woods (2014) - Maturitas
106. Honokiol Decreases Lung Cancer Metastasis through Inhibition of the STAT3 Signaling Pathway.
     Jing Pan, Yongik Lee, Qi Zhang, Donghai Xiong, Tina C Wan, Yian Wang, Ming You (2017) - Cancer prevention research (Philadelphia, Pa.)
107. Effect of a sugar-free chewing gum containing magnolia bark extract on different variables related to caries and gingivitis: a randomized controlled intervention trial.
     G Campus, M G Cagetti, F Cocco, S Sale, G Sacco, L Strohmenger, P Lingström (2011) - Caries research
108. Hypoglycemic effect and mechanism of honokiol on type 2 diabetic mice.
     Jing Sun, Xueqi Fu, Ye Liu, Yongsen Wang, Bo Huo, Yidi Guo, Xuefeng Gao, Wannan Li, Xin Hu (2015) - Drug design, development and therapy
109. Extracts of Magnolia Species-Induced Prevention of Diabetic Complications: A Brief Review.
     Xuezhong Zhao, Fengsheng Li, Wanqing Sun, Ling Gao, Ki Soo Kim, Kyoung Tae Kim, Lu Cai, Zhiguo Zhang, Yang Zheng (2016) - International journal of molecular sciences
110. Magnolol regulates miR-200c-3p to inhibit epithelial-mesenchymal transition and retinoblastoma progression by modulating the ZEB1/E-cadherin axis in vitro and in vivo.
     Yu-Hung Lai, Wei-Lun Liu, Tsung-Ying Lee, Chung-Wen Kuo, Yu-Ru Liu, Chi-Yuan Huang, Yung-Hsiang Chen, I-Ling Chen, Szu-Hui Wu, Shu-Chi Wang, Po-Yen Lee, Ching-Chih Liu, Jung Lo, Yo-Chen Chang, Hsuan-Fu Kuo, Chong-Chao Hsieh, Chia-Yang Li, Po-Len Liu (2023) - Phytomedicine : international journal of phytotherapy and phytopharmacology
111. BMP7 mediates the anticancer effect of honokiol by upregulating p53 in HCT116 cells.
     Rong-Xing Liu, Wen-Yan Ren, Yan Ma, Yun-Peng Liao, Han Wang, Jia-Hui Zhu, Hai-Tao Jiang, Ke Wu, Bai-Cheng He, Wen-Juan Sun (2017) - International journal of oncology
112. Thin-layer chromatographic quantification of magnolol and honokiol in dietary supplements and selected biological properties of these preparations.
     Eliza Łata, Agnieszka Fulczyk, Péter G Ott, Teresa Kowalska, Mieczysław Sajewicz, Ágnes M Móricz (2020) - Journal of chromatography. A

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.